Brokers Set Expectations for XENE Q1 Earnings

Xenon Pharmaceuticals Inc. (NASDAQ:XENE) – Equities researchers at Leerink Partnrs issued their Q1 2025 earnings per share estimates for Xenon Pharmaceuticals in a note issued to investors on Thursday, February 27th. Leerink Partnrs analyst M. Goodman anticipates that the biopharmaceutical company will earn ($0.97) per share for the quarter. The consensus estimate for Xenon Pharmaceuticals’ current full-year earnings is ($3.10) per share. Leerink Partnrs also issued estimates for Xenon Pharmaceuticals’ Q4 2025 earnings at ($1.23) EPS and FY2029 earnings at $2.05 EPS.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.84) EPS for the quarter, topping analysts’ consensus estimates of ($0.89) by $0.05.

Several other equities research analysts have also recently issued reports on XENE. Needham & Company LLC restated a “buy” rating and set a $60.00 price objective on shares of Xenon Pharmaceuticals in a report on Wednesday, November 13th. Deutsche Bank Aktiengesellschaft started coverage on shares of Xenon Pharmaceuticals in a research note on Tuesday, February 11th. They set a “buy” rating and a $67.00 price objective for the company. William Blair reaffirmed an “outperform” rating on shares of Xenon Pharmaceuticals in a research report on Friday. Finally, HC Wainwright reaffirmed a “buy” rating and set a $53.00 price target on shares of Xenon Pharmaceuticals in a research note on Monday, February 24th. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $57.38.

Xenon Pharmaceuticals Stock Performance

Shares of NASDAQ XENE opened at $35.79 on Monday. The firm’s 50 day moving average price is $39.22 and its 200 day moving average price is $40.31. The firm has a market cap of $2.73 billion, a P/E ratio of -12.69 and a beta of 1.20. Xenon Pharmaceuticals has a 1 year low of $33.27 and a 1 year high of $47.80.

Institutional Trading of Xenon Pharmaceuticals

Hedge funds have recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new stake in Xenon Pharmaceuticals during the 4th quarter worth $63,000. Quarry LP acquired a new stake in shares of Xenon Pharmaceuticals during the fourth quarter valued at about $78,000. Blue Trust Inc. increased its position in shares of Xenon Pharmaceuticals by 140.3% during the fourth quarter. Blue Trust Inc. now owns 2,422 shares of the biopharmaceutical company’s stock worth $95,000 after acquiring an additional 1,414 shares during the last quarter. Avior Wealth Management LLC acquired a new position in shares of Xenon Pharmaceuticals in the fourth quarter worth about $101,000. Finally, Mirae Asset Global Investments Co. Ltd. boosted its holdings in Xenon Pharmaceuticals by 21.6% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,740 shares of the biopharmaceutical company’s stock valued at $106,000 after purchasing an additional 487 shares during the last quarter. Hedge funds and other institutional investors own 95.45% of the company’s stock.

Insiders Place Their Bets

In related news, CFO Sherry Aulin sold 18,709 shares of the business’s stock in a transaction that occurred on Wednesday, December 18th. The stock was sold at an average price of $41.21, for a total transaction of $770,997.89. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Ian Mortimer sold 22,468 shares of the company’s stock in a transaction that occurred on Friday, January 24th. The stock was sold at an average price of $40.20, for a total value of $903,213.60. Following the completion of the transaction, the chief executive officer now owns 31,302 shares of the company’s stock, valued at approximately $1,258,340.40. This represents a 41.79 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 57,492 shares of company stock worth $2,334,969 over the last ninety days. 5.52% of the stock is owned by company insiders.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc, a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders.